共 93 条
[1]
Jonassen I(2010)Insulin degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation Diabetes 59 A11-1201
[2]
Havelund S(2015)Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine Expert Opin Drug Metab Toxicol 11 1193-864
[3]
Hoeg-Jensen T(2012)Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes Diabetes Obes Metab 14 859-245
[4]
Bjerre D(2010)Correlates of insulin injection omission Diabetes Care 33 240-886
[5]
Ribel U(2006)Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart Diabet Med 23 879-612
[6]
Heise T(2013)Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, pan-Asian, treat-to-target trial J Diabetes Investig 4 605-2471
[7]
Hövelmann U(2012)Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long) Diabetes Care. 35 2464-1497
[8]
Nosek L(2012)Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin as part in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial Lancet 379 1489-472
[9]
Hermanski L(2013)Effects of switching from insulin glargine or detemir to insulin degludec in patients with type 1 diabetes mellitus Diabetes Ther 4 461-2019
[10]
Bøttcher SG(2015)Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study Diabetologia 58 2013-176